RxDoctor Payments Data

Joseph Hakas, MD

Cardiovascular Disease · Pinehurst, NCNPI 1154366110

Payments from drug & device makers

$62,512in general payments, 2019–2025

Across 61 payments — averaging $1024.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$51K
  • Bayer$6K
  • Novartis$3K
  • Boehringer Ingelheim$1K
  • Boston Scientific$626
  • Abbott$176
  • plus $578 from 13 others

What the payments were for

  • Food & beverage$1,380100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,512 in reported general payments places this provider in the 85th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$323,400
Medicare patients
1,306
Services billed
6,062

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban683$674,537
JardianceEmpagliflozin263$258,334
XareltoRivaroxaban117$121,062
MultaqDronedarone Hcl70$87,266
Repatha SureclickEvolocumab96$85,496
EntrestoSacubitril/Valsartan60$69,949
FarxigaDapagliflozin Propanediol79$63,627
Praluent PenAlirocumab22$15,282
NexletolBempedoic Acid31$13,885
BrilintaTicagrelor20$13,099
Metoprolol Succinate838$12,867
Ranolazine ErRanolazine132$10,864
Dabigatran EtexilateDabigatran Etexilate Mesylate23$7,258
Rosuvastatin Calcium352$4,921
Verapamil SrVerapamil Hcl43$4,763

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$82$674,537683 claims
Boehringer IngelheimJardiance$1,026$258,334263 claims
Johnson & JohnsonXarelto$16$121,062117 claims
AstraZenecaFarxiga, Brilinta$51,441$76,72699 claims
NovartisEntresto$3,035$69,94960 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Pinehurst

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →